Overview

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This study will test the theory that therapy designed for each individual's tumor will improve outcomes over standard of care in a population that needs a better standard.

Phase:

Phase 2

Details

Lead Sponsor:

Bryan Schneider, MD

Collaborators:

Hoosier Cancer Research Network
Strategic Research Initiative Grant through IUSCC
Vera Bradley Foundation for Breast Cancer
Walther Cancer Institute